We spend a lot of time in the poster halls at scientific and medical meetings such as European Society for Medical Oncology (ESMO) Congress in Madrid because that’s where the action is in terms of finding nuggets of promising preclinical and early clinical data. You can also spot new trends emerging earlier this way.

 

At large meetings run by the American Society of Hematology (ASH) and American Association for Research (AACR) there are literally thousands of posters, all of which have passed the grade to merit presentation.

Gaining insights from posters, and in particular, picking those that really matter is often an art rather than a science – a lot of intuition is involved.

This post discusses a few of the posters presented in the developmental therapeutic session at ESMO this year. It focuses on non-immunotherapy topics, i.e. traditional TKIs and monoclonal antibodies to specific mutations or other targets.

Subscribers can login to read more. Do consider supporting our cancer conference coverage by becoming a subscriber.

Thanks for your support!

This content is restricted to subscribers

Posted by